Veracyte Q2 Revenue Beats, Raises 2026 Guidance on Strong Test Sales
VCYT has more than doubled off its 52-week low of $22.92.
Summary
Veracyte delivered a strong Q2, with revenue of $150.3M beating consensus by about 4% and rising 15% year-over-year. Growth was driven by Decipher and Afirma test sales, up 20% and 18% respectively. The company also launched two new cancer tests during the quarter. Management raised full-year 2026 revenue guidance to $590M-$596M, above the prior $582M-$592M range, and expects adjusted EBITDA margin above 26%. This follows a robust Q1 and recent Medicare coverage for the TrueMRD test, reinforcing the commercial momentum. The stock is likely to react positively to the beat and raised outlook.
At the time of this announcement, VCYT was trading at $52.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $22.92 to $60.91. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.